Fulcrum Therapeutics Inc - Ordinary Shares

The momentum for this stock is not very good. Fulcrum Therapeutics Inc - Ordinary Shares has good growth characteristics. Fulcrum Therapeutics Inc - Ordinary Shares is not very popular among insiders. Fulcrum Therapeutics Inc - Ordinary Shares is a mediocre stock to choose.

News

FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Business Wire The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ...\n more…

Fulcrum Therapeutics just downgraded at BofA, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Fulcrum Therapeutics just downgraded at Stifel, here's why

Stifel Nicolaus Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)

TipRanks Financial Blog Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Fulcrum Therapeutics (FULC - Research Report) today and set a price target of $22.00....\n more…

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Globe Newswire Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 Fulcrum to suspend future losmapimod development...\n more…

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded by Bank of America to "Neutral"

Ticker Report Bank of America upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) from an underperform rating to a neutral rating in a report released on Monday, MarketBeat Ratings reports. The...\n more…